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Mutations in breast cancer tumor susceptibility
genes, BRCA1 and BRCA2, predispose women to early
onset breast cancer and other malignancies. The Brca
genes are involved in multiple cellular processes in re-
sponse to DNA damage including checkpoint activation,
gene transcription, and DNA repair. Biochemical inter-
action with the recombinational repair protein Rad51
(Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra,
M., Feunteun, J., and Livingston, D. M. (1997) Cell 90,
425–435), as well as genetic evidence (Moynahan, M. E.,
Chiu, J. W., Koller, B. H., and Jasin, M. (1999) Mol. Cell 4,
511–518 and Snouwaert, J. N., Gowen, L. C., Latour,
A. M., Mohn, A. R., Xiao, A., DiBiase, L., and Koller, B. H.
(1999) Oncogene 18, 7900–7907), demonstrates that Brca1
is involved in recombinational repair of DNA double
strand breaks. Using isogenic Brca11/1 and brca12/2
mouse embryonic stem (ES) cell lines, we investigated
the role of Brca1 in the cellular response to two different
categories of DNA damage: x-ray induced damage and
cross-linking damage caused by the chemotherapeutic
agent, cisplatinum. Immunoflourescence studies with
normal and brca12/2 mutant mouse ES cell lines indi-
cate that Brca1 promotes assembly of subnuclear Rad51
foci following both types of DNA damage. These foci are
likely to be oligomeric complexes of Rad51 engaged in
repair of DNA lesions or in processes that allow cells to
tolerate such lesions during DNA replication. Clono-
genic assays show that brca12/2 mutants are 5-fold more
sensitive to cisplatinum compared with wild-type cells.
Our studies suggest that Brca1 contributes to damage
repair and/or tolerance by promoting assembly of
Rad51. This function appears to be shared with Brca2.
Germ line mutations in BRCA1 or BRCA2 genes result in a
marked increase in the risk of early onset breast and ovarian
cancers (5–10). BRCA1 and BRCA2 appear to have multiple
functions including roles in transcriptional regulation (11–14)
and cell cycle checkpoint control (15–20).1 Brca1 and Brca2
both have transcription activation functions (11, 13); Brca1
co-activates transcription with p53 (21, 22). Recently it has
been demonstrated that Brca1 participates in homologous re-
combinational repair pathways (2, 3). These observations are
consistent with earlier work that demonstrated interaction of
Brca1 and Brca2 with the recombinational repair protein
Rad51, in addition to studies showing that brca1 and brca2
mutants are phenotypically similar to rad51 mutants (1, 4,
23–26).
In addition to contributing to recombinational repair of dou-
ble strand breaks (DSBs),2 BRCA1 has also been implicated in
other DNA repair pathways. Mutational analysis has shown a
role for BRCA1 in transcription-coupled base excision repair of
oxidative DNA damage (27, 28). Furthermore, a recent study
reported biochemical interactions between Brca1 and proteins
required for DNA-end joining, nucleotide mismatch repair,
DNA replication, and signal transduction in response to dam-
age (29). This study also identified interactions between Brca1
and other proteins thought to be involved in recombinational
repair. Although these results raise the possibility that BRCA1
contributes to multiple cellular DNA damage responses, the
specific mechanisms through which BRCA1 contributes to
these processes remain to be determined.
Studies primarily in yeast have indicated that Rad51 pro-
motes homology-dependent repair of DNA DSBs. The strand
exchange activity of Rad51 catalyzes the exchange of genetic
information between a damaged DNA molecule and an undam-
aged template copy (30, 31). Similarly, studies have shown that
the human Rad51 possesses DNA strand-exchange activity
(32). Immunostaining analysis of yeast and mammalian cells
undergoing DNA repair and recombination have revealed the
presence of visible subnuclear assemblies of Rad51 (33, 34).
The properties of Rad51 foci indicate that they are multim-
eric nucleoprotein complexes engaged in recombinational re-
pair (33–38). In mammalian cells, rad51 “knock-out” mice
have been shown to display embryonic lethality and sensitivity
to ionizing radiation indicating a role in mediating genome
stability (26).
Rad51 plays a central role in mediating homologous recom-
bination events and can promote strand-exchange alone in
vitro. However, its strand-exchange activity requires various
accessory factors. For example, one category of accessory factor
promotes assembly of Rad51 into the helical protein-DNA fila-
ments needed for strand exchange. In yeast, biochemical (39–
42) and cytological (36) observations indicate that RPA, Rad55,
Rad57, and Rad52 proteins promote the assembly of Rad51
during yeast meiotic recombination. Thus, one model for Rad51
assembly at sites of damage is that formation of the initial RPA
nucleoprotein complex at single-stranded DNA tracts provides
the necessary structural “platform” for Rad51 to be recruited to
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the damage repair complex (36). This model for Rad51 assem-
bly is supported in mammalian cells by cytological and bio-
chemical co-localization of RPA and Rad51 foci following DNA
damage (43). In addition, the Xrcc3 protein (44, 45) is a likely
candidate for a Rad51 assembly factor based on genetic (45, 46)
and cytological observations (35).3 Hence formation of Rad51
complexes at sites of damage is dependent upon at least two
criteria: (a) formation of a DNA substrate (e.g. single-stranded
DNA tracts) upon which (b) assembly factors form and facili-
tate recruitment of Rad51.
Here we report that in mouse ES cells, Brca1 is required for
formation of subnuclear Rad51 complexes in response to cellu-
lar damage by ionizing radiation or cisplatinum treatment.
Accordingly, cells lacking normal Brca1 function are more sen-
sitive to ionizing radiation (27, 47, 48) and cross-linking agents
(Ref. 49 and this work) compared with normal cells. Our find-
ings are in contrast to those reported recently, in which a role
for BRCA2 in damage-induced assembly of Rad51 was detected
but an equivalent role for BRCA1 was not found (24). We
propose that both Brca1 and Brca2 contribute to recombina-
tional repair by promoting the assembly of Rad51 at the sites of
DNA damage.
EXPERIMENTAL PROCEDURES
Cell Lines—Brca11/1 (E14Tg2a) and brca12/2 isogenic mouse embry-
onic stem (ES) cell lines (50) were grown in Dulbecco’s modified Eagle’s
medium supplemented with 15% fetal bovine serum, nonessential
amino acids, glutamine, penicillin/streptomycin, and murine leukemia
inhibitory factor (ESGRO, Life Technologies, Inc.) and plated on 0.1%
gelatinized 100-mm2 tissue culture plates.
DNA Damage by X-rays and Cisplatinum—Exponentially growing
cultures in 100-mm2 dishes were x-irradiated with a Maxitron genera-
tor (General Electric) at a dose rate of 114 cGy/min. Dishes were
returned to the incubator immediately after treatment. For dose-re-
sponse studies, cells were incubated for 3 h after irradiation before
being harvested as described previously (35). For cisplatinum dose-
response experiments, cultures were washed twice in serum-free me-
dium and then incubated for 1 h in serum-free medium containing
varying concentrations of cisplatinum (Bristol Laboratories). Dishes
were washed three times in serum-free medium, and complete medium
was added. Cultures were then placed at 37 °C for 3 h, at which time a
single-cell suspension was obtained with trypsin/EDTA and the cells
were prepared for immunostaining.
Immunostaining and Microscopy—Cells were immunostained as de-
scribed previously (35). Samples consisted of focus counts from 50
unselected nuclei. The Kruskal-Wallis test was used to determine the
statistical significance of observed differences between samples. Color
images that combine fluorescein and 4,6-diamidino-2-phenylindole
staining patterns were generated by converting grayscale images to
pseudocolor and then merging the patterns electronically using I.P. Lab
Spectrum software (Signal Analytics Corp., Vienna, VA).
Western Analysis—Samples were prepared as described previously
(35). The anti-HsRad51 IgG (a generous gift from Dr. Akira Shinohara)
and anti-CDK2 (Santa Cruz Biotechnology, Santa Cruz, CA) primary
antibodies were used at concentrations of 0.5 and 0.3 mg/ml, respec-
tively. Secondary antibodies (goat anti-rabbit and goat anti-mouse perox-
idase conjugates, Santa Cruz Biotechnology) were used at a 1:2000-fold
dilution. Signals were detected by chemiluminescence (Renaissance,
NEN Life Science Products).
Clonogenic Survival Assays—For cisplatinum treatment, cells were
exposed to drug for 1 h at 37 °C, in liquid medium as described above,
replated (at 400 and 4000 cells/plate), and allowed to grow. 10–12 days
later the colonies were fixed and stained with crystal violet, and sur-
viving cells were scored. Colonies that contained .50 cells were counted
as survivors. All survival experiments were performed in triplicate, and
the means of the surviving fraction of cells were determined. The
number of colonies were normalized for plating efficiency, which was 93
and 74% for the Brca11/1 and brca12/2 cell lines, respectively.
Cell Cycle Analysis—Cycling Brca1 wild-type or mutant cells were
either untreated or incubated with 10 mM cisplatinum under conditions
described above. Cells were returned to growth for 3 h in medium with
full serum and then harvested, washed in phosphate-buffered saline,
and fixed in cold 70% ethanol while vortexing to ensure disaggregation
of cell clumps. After storage on ice for 30 min, cells were washed twice
in phosphate-buffered saline. Cells were then treated with RNase A
(Sigma) for 30 min at 37 °C followed by addition of propidium iodide
(Sigma) for 30 min on ice. Samples were analyzed immediately using a
Becton-Dickinson FACS analyzer, and further data processing was
accomplished using CellQuest software (Becton-Dickinson).
RESULTS AND DISCUSSION
Mouse brca12/2 ES Cells Are Defective in Rad51 Focus For-
mation following X-ray or Cisplatinum Treatment—We em-
ployed an isogenic pair of mouse ES cell lines, bearing either
wild-type Brca11/1 or a brca12/2 mutant (deleted for exon 11,
which encodes 60% of the Brca1 gene) (50) to investigate the
role of Brca1 in assembly of the recombinational repair protein
Rad51. X-rays induce many types of DNA damage including
single and double strand DNA breaks. Cisplatinum induces
formation of inter- and intrastrand cross-linked adducts (Ref.
35 and references therein). To determine if Brca1 function is
required for Rad51 focus formation following induction of dam-
age with these two agents, cycling Brca11/1 and brca12/2 cells
were exposed to varying doses of x-rays or cisplatinum, as
described above. Cells were fixed and stained with anti-
HsRad51 antibody, and nuclei were visualized by fluorescence
microscopy (Fig. 1). Consistent with earlier work in other mam-
malian tissue culture cells (1, 34, 35), examination of Brca11/1
cells revealed a dramatic increase in the number of subnuclear
Rad51 foci in response to both ionizing radiation and cisplati-
num treatment (Fig. 1, top panel). In contrast, the brca1 mu-
tant displayed relatively few Rad51 foci even after relatively
high doses (Fig. 1, bottom panel; Fig. 2A). These results suggest
that Brca1 is required for normal subnuclear assembly of
Rad51 protein in response to DNA damage by x-rays or cis-
platinum. While the brca12/2 cell line was defective relative to
the wild-type control cell line, we did observe induction of a
small number of Rad51 foci in response to x-rays in the brca1
mutant (Fig. 2A). The brca1 mutant displayed a mean-induced
level of 4.7 foci/nucleus with compared 21.7 foci/nucleus in wild
type after x-irradiation (9 Gy).
Brca1 Is Required for Resistance to Cisplatinum—The same
mouse brca12/2 ES line examined here was previously shown
to be more sensitive to x-rays than its isogenic Brca11/1 pro-
genitor at doses higher than 3 Gy (27). In addition, BRCA1-
deficient human cells have also been demonstrated to be sen-
sitive to ionizing radiation (48, 51). A recent study has shown3 S. Takeda, unpublished observations.
FIG. 1. Formation of Rad51 subnuclear foci in response to DNA
damage induced by x-ray and cisplatinum treatment. Mouse
Brca11/1 and brca12/2 ES cells were damaged with either x-rays or
cisplatinum. Induction of Rad51 foci was analyzed following damage by
immunostaining cells with a-Rad51 serum and then counterstaining
with the DNA-specific stain 4,6-diamidino-2-phenylindole to highlight
nuclei. Representative nuclei are displayed from Brca11/1 and brca12/2
mutant ES cells from either untreated, x-ray (9 Gy)-, or cisplatinum (10
mM)-treated cells.
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that in cisplatinum-resistant MCF-7 cells BRCA1 is up-regu-
lated, suggesting that BRCA1 also contributes to cellular re-
sistance to cisplatinum (49). To compare the relative effects of
drug dose on cellular resistance and Rad51 focus formation and
also to provide more direct evidence implicating Brca1 in cis-
platinum resistance, we performed clonogenic survival assays.
In Brca11/1 cells, Rad51 foci were induced at doses of cisplati-
num that are tolerated by most cells. The number of foci in-
duced by the drug reaches a plateau value at about 10 mM,
which corresponds to the maximum dose tolerated without
substantial loss of cell viability (Fig. 2, A and B). Higher doses
of the drug resulted in a dramatic decline in viability and no
further induction of Rad51 foci. The brca12/2 mutant line was
more sensitive to cisplatinum than the wild-type cell line. The
dose of cisplatinum needed to kill 50% of cells was 20 mM in
wild-type and 4 mM for the brca12/2 mutant indicating that the
mutant is 5-fold less resistant to cisplatinum than wild-type
cells. These results are consistent with the hypothesis that
Brca1 makes a contribution to cisplatinum and radiation re-
sistance through its effect on Rad51 focus formation.
The Failure of brca1 Mutant Cells to Produce Rad51 Foci
Cannot Be Explained by Accumulation of Cells in G1—Previous
work suggested that CHO cells do not form Rad51 foci in
response to x-rays in the G1 phase of the cell cycle but can form
such foci in S and G2 phases.
4 Furthermore, analyses in iso-
genic ES cell lines have suggested a role for Brca1 in G2/M
checkpoint control.5 These results raised the possibility that
the effect of the brca1 mutation on damage-induced Rad51 foci
might be mediated indirectly through an effect on cell cycle
progression. We therefore tested the possibility that brca1 mu-
tant cells do not form Rad51 foci because cisplatinum treat-
ment causes the mutant cells to accumulate in G1. Flow cyto-
metric analysis of Brca1 wild-type and mutant ES cells was
carried out following treatment with 10 mM cisplatinum. This
analysis revealed that, 3 h after treatment with cisplatinum,
the fraction of cells in G1 was 34.5% for the mutant compared
with 27.4% for wild type (Fig. 3, Table I). This difference was
too small to account for the difference in the fraction of cells
that failed to form foci after treatment (86% in the mutant
versus 34% in wild type), thus the role of Brca1 in Rad51
assembly cannot be explained as an indirect effect of perturba-
tion of progress through the cell cycle.
Brca1 Is Not Required for Maintaining Normal Levels of
Rad51 Protein—To test if the number of Rad51 foci formed in
Brca1 wild-type and mutant cells treated with radiation or
cisplatinum damage results from changes in Rad51 protein
levels, Western blot analysis was carried out (Fig. 4). Rad51
levels were normalized against CDK2 protein, which is present
throughout the cell cycle and whose steady-state levels in-
crease only modestly (less than 2–3-fold) in S and G2/M (52).
We observed little or no difference in steady-state Rad51 pro-
tein levels in wild-type or mutant cells untreated or treated
with radiation or cisplatinum (Fig. 4, A and B). Therefore, the
changes observed in the number of Rad51 foci observed cyto-
logically with x-irradiation and cisplatinum treatment is not
associated with a corresponding change in Rad51 steady-state
protein levels. The results also indicate that the brca1 defect in
Rad51 focus formation results from a failure to redistribute
Rad51 to subnuclear foci rather than from a failure to express
normal levels of protein.
Brca1 and Cisplatinum-induced Damage—Cisplatinum
forms two types of adducts with DNA: intrastrand and inter-
strand nucleotide cross-links (53). In contrast to other cross-
linking agents, the most abundant cisplatinum adducts formed
4 U. S. Ear, D. Hari, R. R. Weichselbaum, and D. K. Bishop, unpub-
lished data.
5 A. Pace and B. H. Koller, unpublished observations.
FIG. 2. Analysis of Rad51 foci formation and sensitivity to
cisplatinum-induced DNA damage. A, x-ray and cisplatinum dose-
response analysis of Rad51 focus formation in Brca1 wild-type and
mutant cell lines. Cells were damaged as described under “Experimen-
tal Procedures,” and cells returned to growth for 3 h; subsequently cells
were fixed and stained with anti-Rad51 antibody. Images were taken of
50 unselected nuclei, and the number of Rad51 foci were scored. The
mean number of Rad51 foci/nucleus at each dose, from several experi-
ments, was determined and plotted. B, sensitivity of Brca1 wild-type
and mutant ES cell lines toward cisplatinum treatment was analyzed in
a clonogenic survival assay as described under “Experimental Proce-
dures.” Survival curves for ES cells exposed to cisplatinum treatment
are shown. Following treatment, cells were seeded onto 100-mm gela-
tinized plates and grown for 10–12 days, after which time cells were
stained with crystal violet. The number of colonies obtained with un-
treated cells was corrected for plating efficiency and normalized to
100% survival.
FIG. 3. Cell cycle analysis of cisplatinum-treated Brca11/1 and
brca12/2 cell lines. The cell cycle distribution of Brca1 wild-type and
mutant ES cells before and after treatment with 10 mM cisplatinum was
performed by FACS analysis as described under “Experimental Proce-
dures.” Cells were returned to growth for 3 h post-treatment and then
harvested for analysis. The relative amounts of G1, S, and G2 cell
populations were quantitatively determined by a FACS gate. Quantifi-
cation of cell distributions are shown in Table I.
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are the 1,2-d(GG) intrastrand lesions comprising 60–70%,
while the 1,2-d(AG) interstrand lesion constitutes approxi-
mately 20–30% (53). The ability of cisplatinum to form inter-
strand cross-links is shared with other damaging agents in-
cluding mitomycin C, chloronitrosoureas (54, 55), nitrogen
mustards (56), and members of the psoralen family (53, 57).
The intrastrand cross-links formed by cisplatinum are unusual
in that they are refractory to repair via the nucleotide excision
repair and translesion synthesis pathways (58–60). This re-
fractivity likely results from the binding of high mobility group
proteins to the adducts (58–60).
Bacterial and yeast studies demonstrate that repair of inter-
strand cross-links requires both participation of nucleotide ex-
cision repair proteins and recombinational repair proteins (61–
63). Nucleotide excision repair proteins are responsible for
lesion recognition and for single strand incision and/or DSB
formation at the sites of damage. Recombinational repair pro-
teins are responsible for repairing the intermediates formed by
the nucleotide excision repair proteins acting on interstrand
cross-links. The intermediates acted on by recombinational
repair proteins may include DSBs formed by incision of both
strands at the lesion, daughter strand gaps caused when rep-
licative polymerases are blocked by lesions, or DNA ends
formed when polymerases encounter single strand incisions. In
the first case, recombinational repair can be employed to accu-
rately “heal” the DSB using a homologous duplex as a donor of
sequence information; in the latter two cases, recombinational
repair can be used to accurately restore a functional replication
fork. Recombinational repair is also important for restoring
replication forks when unrepaired intrastrand cross-links are
encountered by polymerase (Refs. 64 and 65 and references
therein). As mentioned above, the intrastrand cross-links
formed by cisplatinum are refractory to excision and bypass
repair pathways and are thus likely to cause replication fork
damage.
Brca1 has been implicated in two types of repair, base exci-
sion repair of oxidative damage (thymine glycol) (27) and re-
combinational repair (2, 48). Thus, Brca1 could promote Rad51
assembly by promoting recognition and incision at the sites of
cisplatinum-induced lesions, which in turn leads to Rad51 as-
sembly. The alternative possibility is that Brca1 is involved in
directing assembly of Rad51 at the sites of ssDNA regions that
form at incision-induced DSBs or at sites of blocked replication
forks. We view the alternative possibility as more likely in the
case of cisplatinum-induced damage for the following several
reasons. First, the nucleotide excision repair mechanism,
shown previously to promote excision of cisplatinum-induced
damage, appears to be functional in brca1 mutants (27). In
contrast, recombinational repair of DSBs is defective in these
cells (2). Other observations suggesting that the defect in
Rad51 assembly is not an indirect consequence of an incision
defect indicate that cisplatinum blocks the replicative DNA
polymerase and that such blocks normally induce Rad51 as-
sembly. Specifically, cisplatinum treatment increases the du-
ration of S-phase in CHO cells by slowing the rate of DNA
synthesis (66). Treatment with hydroxyurea blocks DNA syn-
thesis and causes accumulation of Rad51 foci (1) as does treat-
ment with aphidicolin, a drug that directly inhibits DNA po-
lymerase a.6 Taken together these observations lead us to favor
a model in which Brca1 contributes to cisplatinum resistance,
at least in part, by promoting assembly of Rad51 at cisplatin-
damaged replication forks.
Brca1, Brca2, and Rad51—We have demonstrated here that
Brca1 promotes assembly of Rad51 after treatment with cis-
platinum and ionizing radiation, a function that could account
for the role of Brca1 in conferring cellular resistance to these
treatments (27, 48, 51). In contrast to our results with mouse
ES cells, no defect in Rad51 assembly was detected in the
BRCA1-defective human tumor line HCC1937 (24). In the
same study a Brca2 mutant cell line was found to be defective
in Rad51 assembly (24). It is possible that an interspecies
difference in Brca1 function was responsible for the difference
between our results and those of the previous study. We did
find evidence that damage-induced Rad51 foci form in mouse
ES cells, albeit at a reduced efficiency. Such a Brca1-independ-
ent mechanism could be more active in human cells than in
murine cells, thereby accounting for the observed difference.
Alternatively, an undefined genetic difference between the two
brca1-defective cell lines may have been responsible for the
different observations in the two studies. In this context, we
note that the brca1 mutant line used in our study was derived
by a targeted mutation and is thus closely related to the parent
Brca11/1 control line. Finally, it is possible that the immuno-
staining conditions used in our experiments are particularly
sensitive to a structural difference between Rad51-containing
structures that form in Brca11/1 and those that form in
brca12/2 cells. Further studies are needed to determine if hu-
man Brca1 contributes to Rad51 assembly, but our results
raise the possibility that both Brca1 and Brca2 promote repair
of DNA damage by facilitating assembly of Rad51 complexes.
Our observations in mouse ES cells are similar to previous
observations in hamster XRCC3-defective cells (35), human
6 R. Casanova and D. K. Bishop, unpublished observations.
TABLE I
Cell cycle analysis of cisplatin-treated Brca11/1 and brca12/2
cell lines
The cell cycle distribution of Brca1 wild-type and mutant mouse ES
cells before and after treatment with 10 mM cisplatin was performed by
FACS analysis as described under “Experimental Procedures.” Cells
were returned to growth for 3 h post-treatment and then harvested for
analysis. The relative amounts of G1, S, and G2 cell populations were
quantitatively determined by a FACS gate.
Cell-line Cell cyclestage Untreated Cisplatin
%
Brca11/1 G1 36.8 27.4
S 48.4 59.7
G2 14.8 13
brca12/2 G1 30 34.5
S 56.1 60.6
G2 14 5
FIG. 4. Western blot analysis reveal that steady-state Rad51
protein levels are unaffected in Brca11/1 and brca12/2 cells in
response to damage. Whole cell lysates were prepared from asynchro-
nously growing Brca11/1 and brca12/2 cell lines exposed to x-rays (0, 1,
3, 6, 9 Gy) (A) or cisplatinum (0, 1, 5, 10, 25 mM) (B). Lysates were
subjected to Western blot analysis with anti-Rad51 antibody, 40 mg of
total protein was loaded in each lane. Protein levels were normalized to
the steady-state levels of CDK2 protein (using anti-CDK2 antibody),
which is present throughout the cell cycle.
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BRCA2-deficient cells (24), and mouse rad54 mutant fibro-
blasts (67). Recent work in a chicken B-cell lymphoma line adds
Xrcc2, Rad51B, and Rad51C to the growing list of factors that
play a role, either directly or indirectly, in assembly of Rad51 in
response to DNA damage.7 The large number of proteins re-
quired suggests that damage-dependent Rad51 assembly is a
highly regulated process.
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